Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for <i>In Vivo</i> Pharmacological Studies
Nuak1 (NUAK family SnF1-like kinase-1) is a serine-threonine kinase and a member of the AMPK family. Interest in Nuak1 has increased over the years due to the role it plays in several biological processes, from tumor cell invasion and proliferation to Tau stabilization. Nuak1 is expressed in many cancer cell lines and many reports describe this target as an oncogene, the inhibition of which is hypothesized to be valuable for treating various cancer types including glioma. We report here the discovery of Nuak1 inhibitors originating from HTS hit <b>9</b> with excellent selectivity and the subsequent medicinal chemistry optimization program, supported by structural information from the first crystal structures of a Nuak1 chimeric protein which provided insights into the binding modes of our compounds. These efforts yielded a nanomolar cell potent, highly selective and brain penetrant Nuak1 inhibitor UCB9386 (<b>56</b>) suitable for <i>in vivo</i> pharmacological studies for central nervous system (CNS) disorders.
Authors
- Teresa de Haro (ORCID: https://orcid.org/0000-0002-6860-3970)
- S.L. Delker (ORCID: https://orcid.org/0000-0001-6858-3431)
- Claude Delatour
- Eric Jnoff
- Veerle De Wever
- Atul R. Gholap
- Nathalie Van Hijfte
- Adrian Hall (ORCID: https://orcid.org/0000-0001-7869-6835)
- Jan Abendroth (ORCID: https://orcid.org/0000-0002-8229-3243)
- Simon Verheijden (ORCID: https://orcid.org/0000-0002-6523-6837)
- Thierry Demaude
- Mark Calmiano
- Karine G. Poullennec
- Nilesh Gaikwad
- Jean‐Philippe Courade (ORCID: https://orcid.org/0000-0001-6722-2263)
- Á. de Pablo Cárdenas
- Dnyaneshwar Ghavate
- Magdalena Kierkowicz
- Régis Le Mestre
- Katerina Vernerova
- Nivrutti Waghmode
- Naresh Bhuma
- Laurent Calmus
Institutions
- Janssen (Belgium) (BE)
- Urban College of Boston (US)
- University College Birmingham (GB)
- Bone Therapeutics (BE)
- Illumina (United Kingdom) (GB)
- BenevolentAI (United Kingdom) (GB)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1021/acs.jmedchem.4c01237
- Citations
- 4
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.20
Funders
- UCB